These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8969330)

  • 1. Update and evaluation of Australian guidelines. Industry perspective.
    Carmine B
    Med Care; 1996 Dec; 34(12 Suppl):DS226-32. PubMed ID: 8969330
    [No Abstract]   [Full Text] [Related]  

  • 2. Update and evaluation of Australian guidelines. Government perspective.
    Mitchell A
    Med Care; 1996 Dec; 34(12 Suppl):DS216-25. PubMed ID: 8969329
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of pharmacoeconomic guidelines for formulary approval: the Australian experience.
    Langley PC
    Clin Ther; 1993; 15(6):1154-76; discussion 1120. PubMed ID: 8111812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difficult decisions: weighing treatment costs and benefits.
    Wainio JA
    Hosp Technol Ser; 1995 Jan; 14(1):1-3. PubMed ID: 10140805
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical research: outlook from industry.
    Echols R
    Clin Perform Qual Health Care; 1996; 4(2):113-4. PubMed ID: 10156942
    [No Abstract]   [Full Text] [Related]  

  • 6. Health care cost control. Getting on the right track.
    Diede ML; Liliedahl R
    Manag Care; 2002 Feb; 11(2):24-5, 29-33. PubMed ID: 11904910
    [No Abstract]   [Full Text] [Related]  

  • 7. Price, value, and chaos theory in strategic management.
    Coss TA
    J Cardiovasc Manag; 1996; 7(4):21-4. PubMed ID: 10159788
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugmakers exit the comfort zone.
    Singer ID
    State Health Care Am; 2001; ():24-6. PubMed ID: 11521318
    [No Abstract]   [Full Text] [Related]  

  • 9. Managed care guidelines for the economic evaluation of pharmaceuticals.
    Langley PC; Martin RE
    Am J Manag Care; 1997 Jul; 3(7):1013-21. PubMed ID: 10173366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative health systems. France.
    Rosa JJ; Launois R
    Adv Health Econ Health Serv Res Suppl; 1990; 1():179-95. PubMed ID: 10113790
    [No Abstract]   [Full Text] [Related]  

  • 11. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug evaluation and approval process in the European Union.
    San Miguel MT; Vargas E
    Arthritis Rheum; 2006 Feb; 55(1):12-4. PubMed ID: 16463405
    [No Abstract]   [Full Text] [Related]  

  • 13. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 14. Look before you leap.
    Chao DC; Scheinhorn DJ
    Crit Care Med; 2003 Dec; 31(12):2808-9. PubMed ID: 14668622
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curbing industry sponsor's incentive to design post-approval trials that are suboptimal for informing prescribers but more likely than optimal designs to yield favorable results.
    Falit BP
    Seton Hall Law Rev; 2007; 37(4):969-1049. PubMed ID: 18363220
    [No Abstract]   [Full Text] [Related]  

  • 17. Investing in risk management.
    Fiscus PW
    Nat Biotechnol; 1997 Jan; 15(1):88-9. PubMed ID: 9035113
    [No Abstract]   [Full Text] [Related]  

  • 18. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measuring the "payoff" of worksite health strategies.
    Stason WB
    Bus Health; 1984 Mar; 1(4):19-22. PubMed ID: 10310429
    [No Abstract]   [Full Text] [Related]  

  • 20. Integrated delivery systems focus on service delivery after capitation efforts stall.
    Capitation Manag Rep; 2005 Mar; 12(3):32-5. PubMed ID: 15889632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.